Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TN-301 by Tenaya Therapeutics for Diastolic Heart Failure (HFpEF): Likelihood of Approval
TN-301 is under clinical development by Tenaya Therapeutics and currently in Phase I for Diastolic Heart Failure (HFpEF). According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics's TN-301?
TN-301 is a small molecule commercialized by Tenaya Therapeutics, with a leading Phase I program in Diastolic Heart Failure (HFpEF)....